The future of medicine is here today. Dr. Yael Porat, CEO of BioGenCell (www.BioGenCell.net), describes the development of a groundbreaking technology for the automated production of personalized stem-cell therapies. These products, derived from the patient’s own blood, will be available on demand within 24 hours, to save lives and restore the quality of life for the billion people worldwide with blood vessel diseases including heart disease, stroke, PAD and dementia.
Yael Porat, PhD, is founder and CEO of BioGenCell Ltd (www.BioGenCell.net), a biotechnology company focusing on stem cell therapy and regenerative medicine.
Dr. Porat earned her PhD in immunology from the Sackler School of Medicine, Tel-Aviv University.
Prior to founding BioGenCell, she served as head of the Global Biological Development Department at Teva Pharmaceuticals and as CTO at TheraVitae, where she led the translation of innovative research into the production of stem cell-based therapies used to treat patients with severe cardiovascular diseases.
BioGenCell is developing groundbreaking technology for automated production of patient-specific, blood-derived stem-cell-based therapies. The company’s proprietary technology utilizes immune-directed stem-cell specific activity to create cell-based products for a wide range of diseases. BioGenCell’s first line of products targets incurable vascular diseases, such as heart failure, stroke and Peripheral Artery Diseases.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at [ Ссылка ]
